The cell surface receptor CD44 is a glycoprotein belonging to the hyaluronan-binding proteins, termed hyaladherins. CD44 is expressed in a wide variety of isoforms in many cells, and in particular is present on the surface of malignant cells where it is involved in the onset and progression of cancer. In a first attempt to identify novel CD44 binding agents, we first characterized via nuclear magnetic resonance (NMR) techniques, several agents that were reported to bind to hCD44. To our surprise, however, none of these putative CD44 binding agents including peptides, one of which is in phase 2 clinical trial (A6 peptide), and a recently reported fragment hit, were found to significantly interact with recombinant hCD44(21–178). Nonetheless, we further report that a fragment screening campaign, using solution NMR as detection method, identified a viable fragment hit that bound in a potentially functional pocket on the surface of CD44, opposite to the HA binding site. We hypothesize that this pocket could be indirectly associated with the cellular and in vivo activity of the A6 peptide hence providing a novel framework for a possible development of therapeutically viable CD44 antagonists.